Pfizer Statement on Zantac Litigation

NEW YORK, N.Y., August 11, 2022 – Pfizer Inc. (NYSE:PFE) – As disclosed in our filings with the U.S. Securities and Exchange Commission since February 2020, a number of lawsuits have been filed against many defendants, including Pfizer, involving Zantac. Pfizer sold Zantac only between 1998 and 2006, and the withdrawal of Zantac products from the market in 2019 and 2020 did not involve any Pfizer products. Pfizer has significant defenses to this litigation and there are significant legal and factual issues that remain to be addressed by the courts. Pfizer also has substantial indemnification claims against others, which have been acknowledged by several manufacturers in their disclosures.  As a result, we believe at this time that the outcome of the litigation is not likely to be material to Pfizer. 
 

Disclosure Notice 

The information contained in this statement is as of August 11, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. 

This statement contains forward-looking information about lawsuits that have been filed against Pfizer in various federal and state courts related to Zantac, including requests for indemnification, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the risk and impact of an adverse decision or settlement and the adequacy of reserves related to legal proceedings; the uncertainties inherent in research and development; uncertainties and variables inherent in business operating and financial performance, including, among other things, competitive developments and general economic, political, business, industry, regulatory and market conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; uncertainties regarding the impact of COVID-19; and competitive developments. 

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. 
 

Pfizer Contact: 

Media Relations 
+1 (212) 733-1226 
[email protected]

Investor Relations 
+1 (212) 733-4848 
[email protected]